BDBM50019904 CHEMBL3287209::US9533999, ii-1

SMILES: FC(F)(F)Oc1cccc(CN2C(=O)CSc3cccnc23)c1

InChI Key: InChIKey=NCPJHYQGWPFKQN-UHFFFAOYSA-N

Data: 2 IC50

Find this compound or compounds like it in BindingDB or PDB:

Substructure Similarity at least:  must be >=0.5 Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 2 hits for monomerid = 50019904   

Target/Host (Institution)	Ligand	Target/Host Links	Ligand Links	Trg + Lig Links	Ki nM	ΔG° kcal/mole	IC50 nM	Kd nM	EC50/IC50 nM	koff s-1	kon M-1s-1	pH	Temp °C
Intermediate conductance calcium-activated potassium channel protein 4 (Homo sapiens (Human))	BDBM50019904 (CHEMBL3287209 | US9533999, ii-1) Show SMILES FC(F)(F)Oc1cccc(CN2C(=O)CSc3cccnc23)c1 Show InChI InChI=1S/C15H11F3N2O2S/c16-15(17,18)22-11-4-1-3-10(7-11)8-20-13(21)9-23-12-5-2-6-19-14(12)20/h1-7H,8-9H2	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Patents Similars	US Patent	n/a	n/a	52	n/a	n/a	n/a	n/a	n/a	n/a
Boehringer Ingelheim International GmbH US Patent					Assay Description HEK293 cells over-expressing human KCa3.1 are used to measure the effects of compounds in inhibiting the KCa3.1 channel function. The assay is based ...				US Patent US9533999 (2017) BindingDB Entry DOI: 10.7270/Q21V5C4S
					More data for this Ligand-Target Pair
Intermediate conductance calcium-activated potassium channel protein 4 (Homo sapiens (Human))	BDBM50019904 (CHEMBL3287209 | US9533999, ii-1) Show SMILES FC(F)(F)Oc1cccc(CN2C(=O)CSc3cccnc23)c1 Show InChI InChI=1S/C15H11F3N2O2S/c16-15(17,18)22-11-4-1-3-10(7-11)8-20-13(21)9-23-12-5-2-6-19-14(12)20/h1-7H,8-9H2	PDB Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Patents Similars	Article PubMed	n/a	n/a	52	n/a	n/a	n/a	n/a	n/a	n/a
Temple University School of Pharmacy Curated by ChEMBL					Assay Description Inhibition of human KCa3.1 overexpressed in HEK293 cells assessed as thallium influx preincubated for 15 mins followed by thallium/ionomycin addition...				ACS Med Chem Lett 5: 460-1 (2014) Article DOI: 10.1021/ml500090s BindingDB Entry DOI: 10.7270/Q2RJ4M2T
					More data for this Ligand-Target Pair